D-glucarate

D-Glucarate (Calcium D-Glucarate): A Comprehensive Reference

1. Identity: Chemical Names, Natural Sources, and Common Forms

1.1 Chemical Identity

Glucaric acid, also known as glucarate or D-saccharic acid, is an organic compound belonging to the glucuronic acid derivatives, characterized by the oxidation of glucose to carboxylic acid. More precisely, D-glucaric acid is a dicarboxylic acid derived by oxidation of both the aldehyde group and the hydroxymethyl group of D-glucose. The compound is endogenous: D-glucaric acid is a natural non-toxic compound produced in small amounts by mammals, including humans. In mammals, D-glucaric acid and D-glucaro-1,4-lactone are end-products of the D-glucuronic acid pathway.

The principal supplemental form is the calcium salt. Calcium-D-glucarate is the calcium salt of D-glucaric acid, a substance produced naturally in small amounts by mammals, including humans. Calcium D-glucarate is made by combining glucaric acid with calcium to make supplements. Other salts studied in the scientific literature include potassium hydrogen D-glucarate, which has been used in pharmacokinetic research. The glucarate component, not the calcium, is thought to account for its activity.

1.2 Natural Dietary Sources

Glucaric acid is also found in many fruits and vegetables, with the highest concentrations to be found in oranges, apples, grapefruit, and cruciferous vegetables. More precisely quantified, D-glucaric acid content in various fruits and vegetables ranges from about 0.1 g/kg in grapes and lettuce to about 3.5 g/kg in apples and broccoli. The D-glucaric acid content of commonly consumed plant foods ranges from 10 mg/100 g in lettuce and grapes to approximately 350 mg/100 g in bean sprouts, cruciferous vegetables, apples, and grapefruit. Oranges, apricots, cherries, and tomatoes are also significant sources. In one observational study, urinary excretion of glucaric acid was higher in vegetarians than omnivores, possibly due to differences in dietary exposure and/or glucuronidation.

1.3 Common Supplement Forms and Preparations

Calcium D-glucarate is typically available as a dietary supplement that is taken by mouth. It is sold in capsule and tablet form. In the United States, D-glucaric acid is contained in dietary supplements in the form of calcium D-glucarate. While D-glucaro-1,4-lactone is the most pharmacologically active metabolite, D-glucaro-1,4-lactone seems to be the most pharmacologically active of the three metabolic forms, but it is not commercially available. Calcium-D-glucarate administration results in longer inhibition of beta-glucuronidase (five hours versus one hour) than does D-glucaro-1,4-lactone, so it is the compound used. Calcium D-glucarate is therefore preferred for supplemental purposes because it acts as a slow-release precursor to the active lactone. D-glucono-1,4-lactone, sodium D-gluconate, and calcium D-glucarate are non-toxic glucose derivatives occurring naturally in fruits and vegetables.

2. Traditional and Historical Use

D-Glucarate as an isolated or supplemental compound has no documented history of use in any pre-modern herbal, Ayurvedic, Traditional Chinese Medicine, or other classical medicinal tradition. It is not featured in any published WHO monograph, ESCOP monograph, German Commission E monograph, or European Pharmacopoeia entry as a traditional medicinal plant or botanical preparation. Its identification as a discrete bioactive compound, its measurement in plant foods, and its development as a dietary supplement are products of twentieth-century biochemical and pharmacological research. The beneficial properties of different vitamins, minerals, and other micronutrients have been studied for quite some time. But only recently has the potential usefulness of D-glucaric acid and its derivatives in disease prevention been demonstrated.

Indirectly, populations consuming high quantities of the foods richest in glucaric acid — cruciferous vegetables, apples, citrus fruits, and legumes — have historically included these foods in dietary patterns associated empirically with health, but this connection to glucaric acid specifically was not recognized until modern nutritional biochemistry. Research indicates populations that consume large amounts of fruits and vegetables have a lower incidence of cancer. The formal scientific investigation of D-glucaric acid derivatives as potential chemopreventive agents began primarily in the 1980s with the work of researchers such as Zbigniew Walaszek and colleagues in animal tumor models.

3. Key Constituents and Active Compounds

3.1 D-Glucaric Acid (Glucarate)

The parent compound, D-glucaric acid, is the free acid form. The D-glucuronic acid pathway in mammals produces the end products D-glucaric acid and D-glucaro-1,4-lactone. The oxidation of D-glucuronic acid's lactone to D-glucaro-1,4;6,3-dilactone has been attributed to the enzyme D-glucuronolactone dehydrogenase. Mammals, including humans, naturally generate modest amounts of the non-toxic chemical D-glucaric acid.

Separately, a 1986 PubMed study proposed an alternative biosynthetic pathway: in the presence of iron salts and hydrogen peroxide, D-glucuronic acid was converted into D-glucaric acid, a reaction strongly inhibited by free-radical scavengers and ascribed to the action of the hydroxyl radical. The cytochrome P450 system is considered more likely than "glucuronolactone dehydrogenase" to be responsible for the production of D-glucaric acid in vivo.

3.2 D-Glucaro-1,4-Lactone (1,4-GL): The Active Metabolite

One of D-glucaric acid's derivatives is the potent beta-glucuronidase inhibitor D-glucaro-1,4-lactone (1,4-GL). When calcium D-glucarate is ingested, it is converted to D-glucaric acid in the presence of gastric HCl. The body normally maintains an equilibrium between D-glucaric acid and its two metabolites. According to the Alternative Medicine Review monograph, D-glucaric acid is further metabolized in the gastrointestinal tract into three compounds existing in equilibrium and comprised of approximately 40 percent D-glucaric acid, 30 percent D-glucaro-1,4-lactone, and 30 percent D-glucaro-6,3-lactone. These compounds are then transported to the blood and various internal organs, and are subsequently excreted in the urine and bile.

The pharmacokinetic advantage of the calcium salt over free 1,4-GL is notable: when taken directly, D-glucaro-1,4-lactone is metabolized quite quickly and is excreted from the body usually within 1–2 hours of its administration. Calcium D-glucarate, however, is metabolized slowly, remaining in the body for 5 or more hours after ingestion, resulting in maintenance of stable levels of D-glucaro-1,4-lactone for long periods of time.

4. Established Mechanisms of Action

4.1 Inhibition of Beta-Glucuronidase

The primary and best-characterized mechanism of D-glucarate and its active metabolite is inhibition of the enzyme beta-glucuronidase. Oral supplementation of calcium-D-glucarate has been shown to inhibit beta-glucuronidase, an enzyme produced by colonic microflora and involved in Phase II liver detoxification. Beta-glucuronidase plays a central physiological role: beta-glucuronidase is present in the circulation and probably all vertebrate tissues, and is capable of hydrolyzing glucuronide conjugates. This enzyme is also produced by colonic microflora.

During Phase II detoxification, chemical carcinogens, steroid hormones, and other lipid-soluble toxins are conjugated with glucuronic acid in the liver (glucuronidation), and excreted through the biliary tract. Beta-glucuronidase is capable of deconjugating these potential toxins, making it possible for them to be reabsorbed rather than excreted. D-glucaro-1,4-lactone is the metabolite that has been shown to inhibit beta-glucuronidase activity, increasing excretion of conjugated xenobiotic compounds and decreasing activity of harmful substances that are most active in their deconjugated state.

Hydrolysis of the glucuronide moiety can be carried out by beta-glucuronidase present in most tissues, particularly the liver, kidney, spleen, intestinal epithelium, and endocrine and reproductive organs. Thus, circulating inactive glucuronyl conjugates that are destined for excretion are now recognized as potential toxins at target tissues. Inhibition of beta-glucuronidase activity in the liver can therefore be a hepatoprotective mechanism, preventing liver damage due to toxicity.

Elevated beta-glucuronidase activity is associated with an increased risk for various cancers, particularly hormone-dependent cancers such as breast, prostate, and colon cancers. Research has found that reduced blood levels of D-glucaric acid are characteristic of human cancer patients as well as rodents bearing chemically induced tumors.

4.2 Enhancement of Glucuronidation and Enterohepatic Circulation

Calcium-D-glucarate's detoxifying and anticarcinogenic properties are attributed to its ability to increase glucuronidation and excretion of potentially toxic compounds. During Phase II detoxification, chemical carcinogens, steroid hormones, and other lipid-soluble toxins are conjugated with glucuronic acid in the liver, and excreted through the biliary tract. By reducing the beta-glucuronidase viability and activity of intestinal bacteria, salts of D-glucaric acid have been shown to enhance enterohepatic circulation and reduce steady-state levels of cholesterol synthesis, resulting in decreased serum lipid levels.

4.3 Apoptosis, Anti-Proliferative, and Anti-Inflammatory Effects (Preclinical)

Beyond beta-glucuronidase inhibition, preclinical research has identified additional potential mechanisms. Computational systems biology analysis of supplementation of calcium and potassium glucarate salts and their metabolite D-glucaric acid reveals positive effects on mitigation of liver detoxification via four specific molecular pathways: (1) ROS production, (2) deconjugation, (3) apoptosis of hepatocytes, and (4) beta-glucuronidase synthesis. D-glucaric acid improves liver detoxification by downregulating hepatocyte apoptosis, reducing glucuronide deconjugate levels, reducing ROS production, and inhibiting beta-glucuronidase. Antitumorigenic effects of topical calcium glucarate may be due to stimulated differentiation via induction of transglutaminase activity and suppression of proliferation, as well as inhibition of thymidine kinase and aryl hydrocarbon hydroxylase activities, thus preventing carcinogen-DNA binding. In murine skin tumor models, enhanced chemopreventive effects by a topical butyric acid, nicotinamide, and calcium glucarate combination used on murine skin tumors occurred via induced mitochondria-mediated apoptosis, upregulated p21, and downregulated Bcl-2 and mutant p53.

5. Scientific Evidence by Area of Use

5.1 Cancer Chemoprevention

Animal and In Vitro Evidence

The cancer chemoprevention evidence base for D-glucarate is extensive in animal models but limited in humans. Dietary calcium glucarate, as a slow-release form of glucarate, effectively inhibits from 50–70% the chemical induction of tumors in rodent skin, mammary glands, lung, and liver. The glucarate was identified as the active moiety, since equimolar calcium as calcium gluconate had no effect. Specifically in lung cancer models: in animal studies, calcium glucarate reduced the quantity of benzo[a]pyrene-induced lung lesions with mutated K-ras and p53 genes in the post-initiation phase via DNA adduct removal, mutagenic suppression, and anti-inflammatory activity. In colon cancer models, calcium glucarate exerted chemopreventive effects in the post-initiation phase of carcinogenesis, and dietary calcium glucarate also inhibited oral carcinogenesis.

In skin cancer models, topical calcium glucarate suppressed tumor development in murine skin tumors, and enhanced chemopreventive effects were achieved with a topical butyric acid, nicotinamide, and calcium glucarate combination. Other preclinical data suggest topical ursolic acid along with dietary calcium glucarate supplementation could also reduce skin tumor promotion and inflammatory signaling.

Various glucarolactone-based compounds, including calcium glucarate, microencapsulated D-glucaro-1,4-lactone, potassium hydrogen glucarate, and 2,4-di-O-acetyl-D-glucaro-1-lactone, are known to be effective inhibitors of beta-glucuronidase in cells, blood, urine, and in the intestine and liver. By inhibiting beta-glucuronidase, fewer detoxified (glucuronidated) toxins are hydrolyzed and therefore more toxins are excreted. Such glucarolactone-based compounds are therefore useful candidates in the treatment and prevention of various types of cancer.

Human / Clinical Evidence

Human evidence is sparse. The calcium salt of glucaric acid demonstrated anti-cancer activity in patients with breast cancer in a Phase I clinical trial, and in preclinical models of liver, lung, colon, and skin cancers. A key human study is the 1995 review by Heerdt, Young, and Borgen (Israel Journal of Medical Science), which presented the rationale for the use of an agent such as calcium glucarate, which may both change the internal hormonal milieu and also directly detoxify environmental agents responsible for breast cancer, and expressed hope that clinical trials would better elucidate the role for this agent in the chemoprevention of breast cancer. This publication is a review/rationale paper rather than a controlled interventional trial. In one clinical trial, calcium-D-glucarate reduced beta-glucuronidase in a sample of smokers and non-smokers. In this trial, levels of D-glucaric acid and beta-glucuronidase were measured at baseline and every two weeks; researchers observed a consistent reduction of beta-glucuronidase levels as well as increased D-glucaric acid levels. Tolerability in this trial was acceptable: no unusual toxicity was encountered in a Phase I dose escalation study at up to 9.0 g/d, and calcium D-glucarate was well tolerated, even at the highest dose.

Overall, there is not enough evidence to support the use of calcium D-glucarate for preventing cancer in humans. A great deal of research has investigated the role of glucaric acid in preventing and treating cancer, mostly in animals. Several reviews have identified calcium-D-glucarate as a promising candidate for cancer prevention due to its safety and potential benefits on liver detoxification. The evidence strength for cancer chemoprevention in humans is currently very weak: the mechanistic rationale is supported by preclinical data, but large-scale randomized controlled trials in humans have not been completed.

5.2 Estrogen Metabolism and Hormone Regulation

D-glucarate has been investigated for its potential role in modulating estrogen metabolism, specifically through the beta-glucuronidase pathway. In vitro and animal studies suggest inhibition of beta-glucuronidase may prevent carcinogenesis, as well as initiation and promotion of cancer cells. Increased elimination of carcinogens and hormones including estrogen has also been shown. In animal research, several weeks of high-dose calcium-D-glucarate lowered blood estradiol by 23% in animals.

Human evidence for estrogen-modulating effects is limited and indirect. In one clinical trial with 95 women, a combination supplement containing DIM (diindolylmethane) and calcium-D-glucarate — along with several other plant-based nutrients — improved estrogen metabolism after 28 days. This study is confounded by the multi-ingredient nature of the supplement and cannot isolate the contribution of calcium D-glucarate alone. Based on this effect and clinical experience, some health professionals recommend calcium-D-glucarate supplementation at 1,000–3,000 mg daily for conditions involving high estrogen levels, such as PMS, fibroids, and polycystic ovary syndrome. However, there is not enough clinical evidence to support this practice. Other potential clinical applications of oral calcium-D-glucarate include regulation of estrogen metabolism and as a lipid-lowering agent.

The evidence for estrogen-modulating effects in humans must be characterized as preliminary and insufficient. No adequately powered, placebo-controlled randomized trial using calcium D-glucarate as a sole agent for estrogen regulation has been identified in the peer-reviewed literature.

5.3 Lipid-Lowering (Cholesterol)

Purified diets containing calcium D-glucarate or potassium hydrogen D-glucarate markedly lowered serum levels of cholesterol in female Sprague-Dawley rats. The D-glucarates reduced total serum cholesterol in rats by up to 14% (P<0.05) and lowered LDL-cholesterol by up to 35% (P<0.05), but had no effect on HDL cholesterol. The proposed mechanism is via enterohepatic circulation: bile acids are subject to enterohepatic recirculation; if beta-glucuronidase is highly active, bile acids are reabsorbed and sent back to the liver. When calcium D-glucarate inhibits beta-glucuronidase, it forces the body to excrete these bile acids in the feces rather than reabsorbing them.

Regarding human evidence, the Alternative Medicine Review monograph reports that preliminary human results have mirrored the lipid-lowering effects seen in animal models, showing reductions in total serum cholesterol by up to 12 percent and LDL cholesterol by up to 28 percent. However, these preliminary human findings have not been validated in large, well-controlled randomized trials. More studies are needed to understand the utilization of calcium D-glucarate in maintaining healthy cholesterol levels. The overall evidence for lipid-lowering effects is preliminary: robust in animal studies, but insufficiently characterized in humans.

5.4 Liver Detoxification and Hepatoprotection

In the human body, glucaric acid plays a crucial role in liver detoxification and metabolic processes. The computational systems biology research from a 2023 MDPI Nutrients paper found that increasing D-glucaric acid supplementation to 26 mg led to a significant decrease in glucuronide deconjugate levels, indicating that glucaric acid plays a hepatoprotective role by lowering glucuronide deconjugate levels — which are implicated in promoting liver toxicity and subsequent liver damage — attributable to glucaric acid's inhibition of beta-glucuronidase, which catalyzes the deconjugation of endotoxin-glucuronic acid complexes. Animal studies have documented a decrease in beta-glucuronidase activity in breast, liver, colon, skin, lung, and prostate tissue following oral administration of calcium D-glucarate. Direct human clinical trials specifically measuring hepatoprotective endpoints from calcium D-glucarate supplementation have not been identified in the reviewed literature; current liver-related evidence remains mechanistic and preclinical.

5.5 Antioxidant and Antiplatelet Effects

A human platelet model study indexed on PubMed (2010) investigated the antioxidative activity of calcium D-glucarate alongside sodium D-gluconate and D-glucono-1,4-lactone. The purpose of this study was to investigate and compare the effects of these compounds on blood platelets under oxidative stress conditions and to examine their role in thrombin-induced platelet activation. Platelet activation is essential in haemostasis, tumor progression, and allergic and non-allergic inflammation, where reactive oxygen species are involved. This study represents in-vitro evidence using a human platelet model; it does not constitute a clinical trial. The overall evidence base for antioxidant and antiplatelet effects is in vitro only and not validated in clinical settings.

6. Body Systems and Health Areas

• Hepatic / Detoxification system: Glucuronidation is a vital Phase II liver process that attaches glucuronic acid to toxins, drugs, and hormones to make them water-soluble for excretion. D-glucarate supports this pathway by inhibiting the reactivating enzyme beta-glucuronidase.
• Gastrointestinal / Microbiome: Beta-glucuronidase is present in most vertebrate tissues and is capable of hydrolyzing glucuronide conjugates; this enzyme is also produced by colonic microflora. D-glucarate acts in part by inhibiting the microbial production of this enzyme in the colon.
• Endocrine / Hormonal: The glucuronidation pathway is central to the hepatic clearance of steroid hormones; circulating glucuronyl conjugates of steroid hormones and other ligands, in the past generally considered inactive and destined for excretion, are now recognized as still having the potential to interact with target tissues. By maintaining higher glucuronidation throughput, D-glucarate may influence estrogen and androgen clearance.
• Cardiovascular / Lipid metabolism: Via enhanced excretion of bile acids and reduction in enterohepatic recirculation, D-glucarate has demonstrated cholesterol-lowering effects in animal models.
• Oncological / Chemopreventive: Mounting evidence from short- and long-term models shows potential control of the various stages of the carcinogenic process by the beta-glucuronidase inhibitor D-glucaro-1,4-lactone and its precursors, such as D-glucaric acid salts.
• Renal: Urinary excretion of D-glucaric acid is established as a biomarker. Urinary levels of glucaric acid can indicate hepatic drug metabolism and exposure to xenobiotics, reflecting the activity of the glucuronidation pathway.

7. Dosage Forms and Dosages Reported in Studies

Calcium D-glucarate is not an essential nutrient, and thus no deficiency state exists. The appropriate dose of calcium D-glucarate depends on several factors such as the user's age, health, and other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for calcium D-glucarate.

Reported dosages from the scientific and clinical literature include:

• Phase I dose-escalation clinical trial: No unusual toxicity was encountered in a Phase I dose escalation study at up to 9.0 g/d, and calcium D-glucarate was well-tolerated, even at the highest dose.
• Computational/in silico modeling: Simulations were conducted for glucaric acid (GA) supplementation levels of 0 mg, 26 mg, and 52 mg to model hepatoprotective effects on glucuronide deconjugate levels in bile.
• Clinical practice reports (not from RCTs): Based on observed effects and clinical experience, some health professionals recommend calcium-D-glucarate supplementation at 1,000–3,000 mg daily for conditions involving high estrogen levels, such as PMS, fibroids, and polycystic ovary syndrome. These recommendations are not derived from controlled clinical trials.

Supplement products commonly contain 500 mg per capsule, consistent with the commercially available supplement literature, though clinical dosing guidance from regulatory bodies has not been established.

8. Safety Considerations and Drug Interactions

8.1 General Tolerability

Calcium D-glucarate is promoted as an orally bioavailable dietary supplement with potential chemopreventive activity without adverse effects. Calcium D-glucarate seems to be well tolerated. The FDA toxicology review of related compounds noted that calcium saccharate (calcium D-glucarate) is not listed as a probable, possible, or confirmed human carcinogen. No contraindications are known based on the available literature, though data are limited.

8.2 Pregnancy and Lactation

Due to the potential interference with hormonal metabolism, calcium D-glucarate is not recommended for pregnant or nursing women. This precaution is based on the compound's mechanism of action affecting steroid hormone clearance, not on documented adverse outcomes in human gestational studies.

8.3 Drug Interactions via Glucuronidation

The most clinically relevant safety consideration arises from D-glucarate's mechanism of action. Some medicines are changed and broken down by the liver through the process of glucuronidation. Calcium D-glucarate may affect how quickly the liver processes medicines that are primarily broken down through glucuronidation. This could change the blood levels, effects, and side effects of these medicines. Medicines potentially affected include: acetaminophen (Tylenol), estrogen (found in certain pills, patches, creams, rings, or vaginal suppositories), morphine, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. Additional medications listed in the literature include atorvastatin (Lipitor), diazepam (Valium), digoxin, and entacapone.

Calcium D-glucarate might increase how quickly some medications are broken down by the liver. Taking calcium D-glucarate along with medications changed by the liver might decrease the effectiveness of these medications.

8.4 Alcohol Interaction

Alcohol is rated as a moderate concern in combination with calcium D-glucarate. The body breaks down calcium D-glucarate to get rid of it. Alcohol might increase how fast the body gets rid of calcium D-glucarate, potentially decreasing its effectiveness. It is also established in the pharmacological literature that alcoholism is associated with increased urinary excretion of D-glucaric acid, suggesting that alcohol induces hepatic drug-metabolizing enzymes.

8.5 Regulatory Status

The FDA has not reviewed calcium D-glucarate for safety and effectiveness. It is sold in the United States as a dietary supplement under DSHEA regulations without pre-market approval. No established Recommended Dietary Allowance (RDA) or Tolerable Upper Intake Level (UL) has been set by any regulatory body, consistent with its status as a non-essential nutrient.

8.6 Overall Evidence Characterization

The overall scientific evidence supporting the health benefits of D-glucarate (as calcium D-glucarate) remains preliminary. The mechanistic rationale — inhibition of beta-glucuronidase, enhancement of Phase II detoxification, and reduction in enterohepatic recirculation of carcinogens and hormones — is well-supported by biochemical and animal research. Positive results in animal studies do not always mean a similar approach will work in humans. No clinical trials have tested whether calcium D-glucarate has these effects in humans for most of its proposed applications, with the limited exception of biomarker-level Phase I safety/pharmacokinetic data. Robust, randomized, placebo-controlled clinical trials in humans across the key proposed therapeutic areas (chemoprevention, estrogen regulation, lipid-lowering) are lacking, and no clinical evidence supports the use of calcium glucarate for these conditions at this time.

References

• Calcium-D-glucarate – PubMed (Alternative Medicine Review Monograph Abstract, 2002)
• Calcium-D-Glucarate Monograph – Alternative Medicine Review, Vol. 7 No. 4 (2002)
• The biological role of D-glucaric acid and its derivatives: Potential use in medicine – ResearchGate / Walaszek et al.
• D-Glucaric acid content of various fruits and vegetables and cholesterol-lowering effects of dietary D-glucarate in the rat – ScienceDirect (Nutrition Research, 1996)
• Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention – PubMed (Cancer Detection and Prevention, 1997)
• Calcium glucarate as a chemopreventive agent in breast cancer – PubMed (Israel Journal of Medical Sciences, 1995)
• Calcium Glucarate – Memorial Sloan Kettering Cancer Center Integrative Medicine
• Mechanistic Understanding of D-Glucaric Acid to Support Liver Detoxification Essential to Muscle Health Using a Computational Systems Biology Approach – PMC / Nutrients (2023)
• Dietary D-glucarate effects on the biomarkers of inflammation during early post-initiation stages of benzo[a]pyrene-induced lung tumorigenesis in A/J mice – PMC / Oncology Letters (2012)
• Serum β-Glucuronidase Activity Is Inversely Associated with Plant-Food Intakes in Humans – ScienceDirect / Journal of Nutrition (2002)
• A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model – PubMed (2010)
• Biosynthesis of D-glucaric acid in mammals: a free-radical mechanism? – PubMed (1986)
• Mechanisms of lung cancer chemoprevention by D-glucarate – PubMed (CHEST, Phase I Clinical Trial, 2004)
• NCATS Inxight Drugs — Glucaric Acid
• Calcium D-Glucarate – WebMD Vitamins & Supplements
• Calcium D-glucarate: Health Benefits, Side Effects, Uses, Dose & Precautions – RxList
• Production of Glucaric Acid from a Synthetic Pathway in Recombinant Escherichia coli – PMC (Applied and Environmental Microbiology, 2009)
• B Vitamins, Glucuronolactone and the Immune System: Bioavailability, Doses and Efficiency – PMC (2024)